Matteson, Eric L. http://orcid.org/0000-0002-9866-0124
Aringer, Martin
Burmester, Gerd R.
Mueller, Heiko
Moros, Lizette
Kolb, Martin
Article History
Received: 21 December 2022
Revised: 28 April 2023
Accepted: 2 May 2023
First Online: 20 May 2023
Compliance with ethical standards
:
: The INBUILD trial was conducted in accordance with the protocol, the principles of the Declaration of Helsinki, and the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation and was approved by local authorities.
: Written informed consent was obtained from all patients before study entry.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: Eric L Matteson reports royalties from UpToDate; consulting fees from Alvotech and Boehringer Ingelheim (BI); fees for speaking from BI and Practice Point Communications; has participated on Data Safety Monitoring Boards or Advisory Boards for Horizon Therapeutics and the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); has served on a Committee/Task Force for the American College of Rheumatology. Martin Aringer reports consulting fees for advisory boards and fees for lectures from BI and Roche. Gerd R Burmester reports consulting fees from and has served on speakers’ bureaus for AbbVie, Bristol Myers Squibb, BI, Gilead, Lilly, Merck Sharpe and Dohme, Pfizer, Sanofi, Roche. Heiko Mueller and Lizette Moros are employees of BI. Martin Kolb reports research funding from BI, Pieris and Roche; consulting fees from AbbVie, Algernon, Bellerophon, BI, Cipla, CSL Behring, Horizon, LabCorp, Roche, ShouTi, United Therapeutics; fees for speaking from BI, Novartis, Roche; payment for expert testimony from Roche; has participated on Data Safety Monitoring Boards or Advisory Boards for LabCorp and United Therapeutics; and receives an allowance as Chief Editor of the <i>European Respiratory Journal</i>.